TABLE 2.
Prognostic role of locoregional lymph node metastasis on recurrence and survival
| LN status | No. of patients | RFS (months) | Pa | No. of patients | DSS (months) | Pc |
|---|---|---|---|---|---|---|
| Mesorectum | ||||||
| Positive | 5 | 31 (5–78) | 0.85 | 5 | 40 (21–51) | 0.78 |
| Negative | 15 | 15 (8–77) | 12 | 26 (10–34) | ||
| Inguinal | ||||||
| Positivea | 9 | 8 (3–NR) | 0.94 | 6 | 21 (8–34) | 0.06 |
| Negativeb | 19 | 7 (5–77) | 17 | 29 (13–60) | ||
| Any location | ||||||
| Positive | 13 | 8 (3–78) | 0.59 | 11 | 21 (13–40) | 0.42 |
| Negative | 15 | 15 (8–76) | 12 | 27 (10–34) |
Data are presented as median (interquartile range)
DSS disease-specific survival, LN lymph node, RFS recurrence-free survival, NR not reached
a
Histologically proven metastatic disease of the groin
b
No evidence of metastatic disease at the inguinal lymph nodes, by clinical examination
c
Kaplan-Meier product-limit method